Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 54, Issue 9, 2015, Pages 1640-1649

  Michaud, Kaleb ^a,b   Strand, Vibeke ^c   Shadick, Nancy A ^d   Degtiar, Irina ^e   Ford, Kerri ^f   Michalopoulos, Steven N ^e   Hornberger, John ^e,g  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NATIONAL DATA BANK FOR RHEUMATIC DISEASES   (United States)

^c STANFORD UNIVERSITY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e Cedar Associates   (United States)

^f Crescendo Bioscience   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Health economics; Outcome assessment; Quality of life; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; BLOOD EXAMINATION; CLINICAL EVALUATION; CLINICAL PRACTICE; CONTROLLED STUDY; COST CONTROL; DATA BASE; EMPLOYER; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIBIOMARKER DISEASE ACTIVITY TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RHEUMATOID ARTHRITIS;

EID: 84943226196     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev023     Document Type: Article

References (47)

1. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 2006;36:182-8.
2. Wasserman AM. Diagnosis and management of rheumatoid arthritis. Am Fam Physician 2011;84: 1245-52.
3. Michaud K, Vera-Llonch M, Oster G. Mortality risk by functional status and health-related quality of life in patients with rheumatoid arthritis. J Rheumatol 2012;39: 54-9.
4. Crowson CS, Liang KP, Therneau TM, Kremers HM, Gabriel SE. Could accelerated aging explain the excess mortality in patients with seropositive rheumatoid arthritis? Arthritis Rheum 2010;62:378-82.
5. Plant MJ, Williams AL, O'Sullivan MM et al. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:1473-7.
6. Mottonen T, Hannonen P, Korpela M et al. Delay to institution of therapy and induction of remission using singledrug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46:894-8.
7. Albrecht K, Kruger K, Wollenhaupt J et al. German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic diseasemodifying antirheumatic drugs. Rheumatol Int 2014;34: 1-9.
8. Bykerk VP, Akhavan P, Hazlewood GS et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 2012;39:1559-82.
9. Singh JA, Furst DE, Bharat A et al. 2012 update of the 2008. American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39.
10. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73: 492-509.
11. Marhadour T, Jousse-Joulin S, Chales G et al. Reproducibility of joint swelling assessments in long-lasting rheumatoid arthritis: influence on disease activity score-28 values (SEA-Repro study part I). J Rheumatol 2010;37:932-7.
12. Brown AK, Conaghan PG, Karim Z et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008;58:2958-67.
13. Pollard LC, Kingsley GH, Choy EH, Scott DL. Fibromyalgic rheumatoid arthritis and disease assessment. Rheumatology 2010;49:924-8.
14. Wolfe F, Michaud K, Busch RE et al. Polysymptomatic distress in patients with rheumatoid arthritis: understanding disproportionate response and its spectrum. Arthritis Care Res 2014;66:1465-71.
15. Hobbs KF, Cohen MD. Rheumatoid arthritis disease measurement: a new old idea. Rheumatology 2012; 51(Suppl 6):vi21-7.
16. van der Heijde D, Breedveld FC, Kavanaugh A et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol 2010;37:2237-46.
17. Pincus T, Segurado OG. Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count. Ann Rheum Dis 2006;65:820-2.
18. Centola M, Cavet G, Shen Y et al. Development of a multibiomarker disease activity test for rheumatoid arthritis. PLoS One 2013;8:e60635.
19. Curtis JR, van der Helm-van Mil AH, Knevel R et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res 2012;64:1794-803.
20. Bakker MF, Cavet G, Jacobs JW et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis 2012;71:1692-7.
21. Hirata S, Dirven L, Shen Y et al. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology 2013;52:1202-7.
22. van der Helm-van Mil AH, Knevel R, Cavet G, Huizinga TW, Haney DJ. An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatology 2013;52:839-46.
23. Li W, Sasso EH, Emerling D, Cavet G, Ford K. Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use. Curr Med Res Opin 2013;29:85-92.
24. Suter LG, Fraenkel L, Braithwaite RS. Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management. Arch Intern Med 2011;171:657-67.
25. Finckh A, Bansback N, Marra CA et al. Treatment of very early rheumatoid arthritis with symptomatic therapy, diseasemodifying antirheumatic drugs, or biologic agents: a costeffectiveness analysis. Ann Intern Med 2009;151:612-21.
26. Wailoo AJ, Bansback N, Brennan A et al. Biologic drugs for rheumatoid arthritis in the Medicare program: a costeffectiveness analysis. Arthritis Rheum 2008;58:939-46.
27. US Bureau of Labor Statistics. Division of Consumer Prices and Price Indexes. Consumer Price Index, 2013. US Bureau of Labor Statistics. Washington, DC, USA, 2013.
28. Emery P, Fleischmann R, van der Heijde D et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 2011;63:1200-10.
29. Michaud K, Wallenstein G, Wolfe F. Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: a longitudinal study of 18,485 patients. Arthritis Care Res 2011;63: 366-72.
30. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784-92.
31. Plant MJ, O'Sullivan MM, Lewis PA et al. What factors influence functional ability in patients with rheumatoid arthritis. Do they alter over time? Rheumatology 2005;44: 1181-5.
32. Centers for Medicare & Medicaid Services. Survey of drug acquisition costs paid by retail community pharmacies 2013. (part II) (May 16, 2013). Baltimore, MD, USA: Centers for Medicare & Medicaid Services, 2013.
33. Centers for Medicare & Medicaid Services. Healthcare Common Procedure Coding System. Payment allowance limits for Medicare part B drugs (June 7, 2013). Baltimore, MD, USA: Centers for Medicare & Medicaid Services, 2013.
34. Grijalva CG, Chung CP, Arbogast PG et al. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 2007;45(10 Suppl 2):S66-76.
35. Wailoo A, Brennan A, Bansback N et al. Modeling the cost effectiveness of etanercept, adalimumab and anakinra compared to infliximab in the treatment of patients with rheumatoid arthritis in the Medicare program: final report. Rockville, MD, USA: Agency for Health Care Research and Quality, 2006.
36. US Bureau of Labor Statistics. Current employment statistics (CES) survey: real earnings. Washington, DC, USA: Bureau of Labor Statistics. February 2014.
37. Cush JJ. Trends in rheumatology practice: a survey of US rheumatologists. Paper presented at the American College of Rheumatology Annual Scientific Meeting. San Francisco, CA, 24-28 October 2008.
38. Demaria L, Acelajado MC, Luck J et al. Variations and practice in the care of patients with rheumatoid arthritis: quality and cost of care. J Clin Rheumatol 2014;20:79-86.
39. Wakefield RJ, Gibbon WW, Conaghan PG et al. The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. Arthritis Rheum 2000;43:2762-70.
40. Sharp JT, Gardner JC, Bennett EM. Computer-based methods for measuring joint space and estimating erosion volume in the finger and wrist joints of patients with rheumatoid arthritis. Arthritis Rheum 2000;43:1378-86.
41. McGonagle D, Conaghan PG, O'Connor P et al. The relationship between synovitis and bone changes in early untreated rheumatoid arthritis: a controlled magnetic resonance imaging study. Arthritis Rheum 1999;42: 1706-11.
42. Schoels M, Wong J, Scott DL et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:995-1003.
43. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions-standardizing data on outcomes. N Engl J Med 1998;339:380-6.
44. Berwick DM, Nolan TW, Whittington J. The Triple Aim: care, health, and cost. Health Affairs 2008;27:759-69.
45. Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices-overview: a report of the ISPORSMDM Modeling Good Research Practices Task Force-1. Value Health 2012;15:796-803.
46. Lee SJ, Chang H, Yazici Y et al. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study. J Rheumatol 2009;36:1611-7.
47. Yazici Y, Shi N, John A. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis 2008;66:77-85.